



Stephen R. Cunningham, MD  
Vice President & Head  
USCDMA

Novartis Pharmaceuticals Corporation  
One Health Plaza  
Bldg. 701/184  
East Hanover, NJ 07936

Tel 862.778.4304  
Fax 973.515.0917  
Internet: [stephen.cunningham@pharma.novartis.com](mailto:stephen.cunningham@pharma.novartis.com)

May 5, 2004

## Distribution Changes for Lamprene®

Dear Doctor:

As a regular prescriber of Lamprene® (clofazimine), you may already be aware that Novartis has joined with the World Health Organization (WHO) to eradicate leprosy. As part of this commitment, we will provide Lamprene *free of charge* to patients around the world.

In the United States, our partner in this effort is the National Hansen's Disease Programs (NHDP), a unit of the US Department of Health and Human Services, based in Baton Rouge, Louisiana. When US wholesalers and pharmacies deplete their inventories of Lamprene later this year, the product will no longer be sold in pharmacies and will only be distributed under an Investigational New Drug (IND) application held by NHDP.

Beginning approximately July 1, 2004, or whenever existing inventories are actually exhausted, all requests for Lamprene for the treatment of leprosy should be directed to:

Renee Painter  
Administrative Officer  
Laboratory Research Branch  
RPAINT1 @ LSU.EDU  
Skip Bertman Drive  
Baton Rouge LA 70803  
Phone: (225) 578-9861  
Fax: (225) 578-9856

To receive Lamprene for use in the treatment of leprosy, you must be enrolled as an investigator under the IND held by NHDP. Ms. Painter will provide you with the necessary paperwork for this process. As an investigator, you will be required to provide on an annual basis safety information about the use of Lamprene in your patients.


In addition, the FDA has requested that Lamprene be available for the treatment of multi-drug-resistant tuberculosis (MDRTB). For this purpose, Lamprene will be distributed via single patient INDs administered by the Food and Drug Administration (FDA). All requests for use of Lamprene for the treatment of MDRTB must be directed to:

Division of Special Pathogen and Immunologic Drug Products (HFD-590)  
Center for Drug Evaluation and Research  
Food and Drug Administration  
(301) 827-2127

Upon approval of the patient IND, the FDA will request NHDP to distribute Lamprene directly to the prescriber.

If you have any questions about this process, please contact Novartis at 1-888-NOW-NOVA between 9:00 AM and 5:00 PM Eastern Time, Monday through Friday.

Sincerely,



Stephen Cunningham, MD  
Vice President and Head  
US Clinical Development & Medical Affairs  
Novartis Pharmaceuticals Corporation

*Please see complete prescribing information for Lamprene enclosed.*